Results 161 to 170 of about 10,665,939 (329)
Toward a Behavioral Reserve Model in Amyotrophic Lateral Sclerosis
Annals of Neurology, EarlyView.Objective
Behavioral impairment is common in amyotrophic lateral sclerosis (ALS) and strongly affects autonomy, caregiver burden, and outcomes, yet predictors of vulnerability remain unclear. We investigated whether premorbid regulatory traits and socio‐educational exposures are associated with behavioral phenotypes in ALS within a behavioral reserve ...Francesca Palumbo, Barbara Iazzolino, Cristina Moglia, Umberto Manera, Enrico Matteoni, Sara Cabras, Giorgio Pellegrino, Emilio Minerva, Vita Passidomo, Rosario Vasta, Gabriele Mora, Fabrizio D’Ovidio, Antonio Canosa, Andrea Calvo, Adriano Chiò +14 morewiley +1 more sourceCluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk Factor
, 2023 : Objective: The objective of this study was to aggregate data for the first genomewide association study meta-analysis of cluster headache, to identify genetic risk variants, and gain biological insights. Methods: A total of 4,777 cases (3,348 men and 1,Lund, Nunu, Borte, Sigrid, Fourier, Carmen S., Riedel-Heller, Steffi, Jensen, Rigmor H., Bacchelli, Elena, Pirinen, Matti, Skogholt, Anne Heidi, Guerzoni, Simona, Chen, Shih-Pin, Pedersen, Ole E., Tronvik, Erling, Winsvold, Bendik, Heinze, Katja, Noordam, Raymond, K\ufc\ue7\ufckali, Fahri, Vandrovcova, Jana, Kubisch, Christian, Danno, Daisuke, Mehta, Dwij R., Vijfhuizen, Lisanne, van Dijk, Ko Willems, Wagner, Michael, Ferkingstad, Egil, Tripathi, Kumar Parijat, Ribases, Marta, Wang, Yen-Feng, Steinberg, Anna, Stefansson, Kari, Gallardo, Victor J., Sleegers, Kristel, Belin, Andrea C., Ramirez, Alfredo, Yip, Janice, O'Connor, Emer, Kristoffersen, Espen S., Kelderman, Tim, Terwindt, Gisela C., Zoli, Michele, Dardiotis, Efthimios, Trembath, Richard C., Vikelis, Michail, Happola, Paavo, Wilbrink, Leopoldine A., Paemeleire, Koen H., Magnusson, Sigurdur, de Boer, Irene, Hautakangas, Heidi, Waldenlind, Elisabet, Bjornsdottir, Gyda, Chalmer, Mona, Ramos-Quiroga, Josep A., Fann, Cathy Shen-Jang, Gabrielsen, Maiken E., Pani, Luca, Heinze, Axel, Ostrowski, Sisse S., Petersen, Anja H., Quinn, Olivia, Sveinsson, Olafur, Hansen, Thomas F., Fronczek, Rolf A., Scherer, Martin, Artigas, Maria S., Cainazzo, Maria Michela, Volk, Alexander, Cirkel, Anna, Southgate, Laura, Harder, Aster V. E. A., Thorgeirsson, Thorgeir E., Heilmann-Heimbach, Stefanie E., Guobjartsson, Daniel F., Ran, Caroline, Sivakumar, Prasanth, Thomas, Laurent F., Goebel, Hartmut A., Adebimpe, Joycee, Dalmasso, Maria Carolina, Callesen, Ida, Olofsgard, Felicia Jennysdotter, Lagrata, Susie, Goebel, Carl E., Zwart, John-Anker, Matharu, Manjit, Martinsen, Amy E., Rosendaal, Frits R., Houlden, Henry, Hsu, Chia-Lin, Sjostrand, Christina, Pozo-Rosich, Patricia, Stefansson, Hreinn, van den Maagdenberg, Arn M. J. M., Maestrini, Elena +92 morecore Neurotransmitter‐Defined Degeneration Patterns in Sporadic and C9orf72‐Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems—Implications for Therapy Development
Annals of Neurology, EarlyView.Objective
Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential ...Marlene Tahedl, We Fong Siah, Jasmin Lope, Jennifer C. Hengeveld, Mark A. Doherty, Russell L. McLaughlin, Orla Hardiman, Ee Ling Tan, Alison Toomey, Jana Kleinerova, Peter Bede +10 morewiley +1 more sourceEstablishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3
Annals of Neurology, EarlyView.Repeat expansion disorders frequently involve peripheral neuropathy, yet mechanisms remain unclear. Using a spinocerebellar ataxia type 3 (SCA3) Knock‐In Atxn3Q300/Q6, we identify progressive sensorimotor deficits, peripheral nerve pathology, and dorsal root ganglia RNA splicing dysregulation.Juan P. Mato, John M. Hayes, Jacen Emerson, Maeha Sridharan, Toluwani Adelaja, Arsal Naeem, Alexandra F. Putka, Hayley S. McLoughlin +7 morewiley +1 more sourceAccelerated Brain Atrophy in Epilepsy: A Prospective Population‐Based Study
Annals of Neurology, EarlyView.Objective
Previous longitudinal neuroimaging studies suggest that epilepsy is a progressive disorder. To date, these findings have relied largely on populations from tertiary centers, resulting in ascertainment bias, as severely affected individuals are more likely to be rescanned.Marian Galovic, Rebecca S. N. Liu, Alex D. Everitt, Robert Terziev, Louis Lemieux, Matthias J. Koepp, John S. Duncan +6 morewiley +1 more sourcePerceptions, understandings and experiences of cluster headache patients in the north of England: a qualitative study
, 2015 Background: Very few qualitative studies on cluster headache have been conducted. As a result we have little in-depth understanding of the perceptions and experiences of cluster headache patients and the health professionals who treat them.Ahmed, F., Goadsby, P. J., Quarshie, V., Paemeleire, K., Dikomitis, L. +4 morecore Cortical Thickness and White Matter Surface Morphology in Tourette Syndrome: A Cohort Study
Annals of Neurology, EarlyView.Objective
To examine cortical thickness and white matter surface morphology in a large sample of individuals with Tourette syndrome (TS) and neurotypical controls across the lifespan, and to assess associations with symptom severity, comorbidities, and medication use.Sahar Delavari, Adam C. Frank, Ravi Bansal, Flora M. Vaccarino, Robert A. King, Paul Lombroso, Lawrence Scahill, James F. Leckman, Bradley S. Peterson +8 morewiley +1 more sourceTherapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model
Annals of Neurology, EarlyView.Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34‐year‐old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning ...Francois Ricordeau, Sebastien Arthaud, Leila Langbour, Silvia Melzi, Aurelie Richard‐Mornas, Hannah Doudoux, Benjamin Rolland, Laure Peter‐Derex, Christelle Peyron +8 morewiley +1 more source